Results 1 to 10 of about 3,300,951 (351)

Purging viral latency by a bifunctional HSV-vectored therapeutic vaccine in chronically SIV-infected macaques [PDF]

eLife
The persistence of latent viral reservoirs remains the major obstacle to eradicating human immunodeficiency virus (HIV). We herein found that ICP34.5 can act as an antagonistic factor for the reactivation of HIV latency by herpes simplex virus type I ...
Ziyu Wen, Pingchao Li, Yue Yuan, Congcong Wang, Minchao Li, Haohang Wang, Minjuan Shi, Yizi He, Mingting Cui, Ling Chen, Caijun Sun   +10 more
doaj   +2 more sources

Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B

Vaccines, 2022
Nasvac (HeberNasvac®) is a novel therapeutic vaccine for chronic hepatitis B (CHB). This product is a formulation of the core (HBcAg) and surface (HBsAg) antigens of the hepatitis B virus (HBV), administered by nasal and subcutaneous routes, in a ...
Julio Cesar Aguilar, Jorge Agustin Aguiar, Sheikh Mohammad Fazle Akbar   +2 more
doaj   +1 more source

Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics

Vaccines, 2021
Typhoid fever remains a significant health problem in sub-Saharan Africa, with incidence rates of >100 cases per 100,000 person-years of observation. Despite the prequalification of safe and effective typhoid conjugate vaccines (TCV), some uncertainties ...
Andrea Haekyung Haselbeck, Birkneh Tilahun Tadesse, Juyeon Park, Malick M. Gibani, Ligia María Cruz Espinoza, Ariane Abreu, Craig Van Rensburg, Michael Owusu-Ansah, Sampson Twuamsi-Ankrah, Michael Owusu, Isaac Aguna, Valentina Picot, Hyonjin Jeon, Ellen Higginson, Sunju Park, Zenaida R. Mojares, Justin Im, Megan E. Carey, Farhana Khanam, Susan Tonks, Gordon Dougan, Deokryun Kim, Jonathan Sugimoto, Vittal Mogasale, Kathleen M. Neuzil, Firdausi Qadri, Yaw Adu-Sarkodie, Ellis Owusu-Dabo, John Clemens, Florian Marks   +29 more
doaj   +1 more source

Madagascar's EPI vaccine programs: A systematic review uncovering the role of a child's sex and other barriers to vaccination

Frontiers in Public Health, 2022
BackgroundImmunizations are one of the most effective tools a community can use to increase overall health and decrease the burden of vaccine-preventable diseases.
Emma Hahesy, Ligia Maria Cruz-Espinoza, Gabriel Nyirenda, Birkneh Tilahun Tadesse, Jerome H. Kim, Florian Marks, Florian Marks, Florian Marks, Raphael Rakotozandrindrainy, Wibke Wetzker, Andrea Haselbeck   +10 more
doaj   +1 more source

Mitigating the effects of climate change on human health with vaccines and vaccinations

Frontiers in Public Health, 2023
Climate change represents an unprecedented threat to humanity and will be the ultimate challenge of the 21st century. As a public health consequence, the World Health Organization estimates an additional 250,000 deaths annually by 2030, with resource ...
Cara Lynn Kim, Suneth Agampodi, Suneth Agampodi, Florian Marks, Florian Marks, Florian Marks, Florian Marks, Jerome H. Kim, Jerome H. Kim, Jean-Louis Excler   +9 more
doaj   +1 more source

A Race against Time: Reduced Azithromycin Susceptibility in Salmonella enterica Serovar Typhi in Pakistan

mSphere, 2020
Antimicrobial resistance is an ongoing issue in the treatment of typhoid fever. Resistance to first-line antimicrobials and extensively drug resistant (XDR) Salmonella Typhi isolates in Pakistan have left azithromycin as the only remaining effective oral
Junaid Iqbal, Irum F. Dehraj, Megan E. Carey, Zoe A. Dyson, Denise Garrett, Jessica C. Seidman, Furqan Kabir, Senjuti Saha, Stephen Baker, Farah N. Qamar   +9 more
doaj   +3 more sources

Pulmonary Infection Caused by Mycobacterium malmoense in a Chronic HIV-Infected Individual Participating in a Therapeutic Vaccine Trial

Vaccines, 2021
We report a case of Mycobacterium malmoense pulmonary infection and HIV-1 chronic co-infection in a 60-year-old man while participating in an HIV-1 therapeutic vaccine clinical trial and during the analytical treatment interruption.
Joana Silva Marques, Marta Bodro, Berta Torres, Felipe García, José Antonio Martínez, Lorna Leal   +5 more
doaj   +1 more source

Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]

, 2020
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core   +2 more sources

Design and Immunological Validation of Macaca fascicularis Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs

Frontiers in Immunology, 2021
Persistent human papillomavirus (HPV) infections are causative for cervical neoplasia and carcinomas. Despite the availability of prophylactic vaccines, morbidity and mortality induced by HPV are still too high.
Patrick Neckermann, Ditte Rahbaek Boilesen, Ditte Rahbaek Boilesen, Torsten Willert, Cordula Pertl, Silke Schrödel, Christian Thirion, Benedikt Asbach, Peter Johannes Holst, Peter Johannes Holst, Ralf Wagner, Ralf Wagner   +11 more
doaj   +1 more source

Therapeutic HPV vaccines [PDF]

Best Practice & Research Clinical Obstetrics & Gynaecology, 2018
High-risk human papillomavirus (HPV) infection is known to be a necessary factor for cervical and anogenital malignancies. Cervical cancers account for over a quarter of a million deaths annually. Despite the availability of prophylactic vaccines, HPV infections remain extremely common worldwide.
Hancock, G, Hellner, K, Dorrell, L
openaire   +3 more sources